Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).

被引：0
|
作者：
Aapro, Matti S.
Rossi, Giorgia
Rizzi, Giada
Palmas, Marco
Grunberg, Steven
机构：
[1] Clin Genolier, Genolier, Switzerland
[2] Helsinn Healthcare SA, Lugano, Switzerland
[3] Fletcher Allen Hlth Care, Burlington, VT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA9514
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
    Zhang, L.
    Lu, S.
    Feng, J.
    Dechaphunkul, A.
    Chang, J.
    Wang, D.
    Chessari, S.
    Lanzarotti, C.
    Jordan, K.
    Aapro, M.
    ANNALS OF ONCOLOGY, 2018, 29 (02) : 452 - 458
  • [22] Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)
    Baron-Hay, Sally
    Aapro, Matti
    Bernareggi, Alberto
    Schwartzberg, Lee
    SUPPORTIVE CARE IN CANCER, 2019, 27 (04) : 1309 - 1317
  • [23] Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)
    Sally Baron-Hay
    Matti Aapro
    Alberto Bernareggi
    Lee Schwartzberg
    Supportive Care in Cancer, 2019, 27 : 1309 - 1317
  • [24] Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
    Hesketh, P. J.
    Rossi, G.
    Rizzi, G.
    Palmas, M.
    Alyasova, A.
    Bondarenko, I.
    Lisyanskaya, A.
    Gralla, R. J.
    ANNALS OF ONCOLOGY, 2014, 25 (07) : 1340 - 1346
  • [25] NEPA, AN ORAL FIXED COMBINATION OF NETUPITANT AND PALONOSETRON, IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN GERMANY AND GREECE
    Bourhis, F.
    Eriksson, J.
    Ruffo, P.
    D'Agostino, P.
    Turini, M.
    VALUE IN HEALTH, 2018, 21 : S43 - S44
  • [26] NETUPITANT AND PALONOSETRON (NEPA), IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN SINGAPORE
    Lim, S. W.
    Loh, K. W. J.
    Boisseau, S.
    Ho, W. T.
    Qasuri, M.
    D'agostino, P.
    Turini, M. M.
    Bourhis, F.
    Eriksson, J.
    Hadjiat, Y.
    VALUE IN HEALTH, 2019, 22 : S475 - S476
  • [27] Improving the functional status of patients with cancer by more effectively preventing chemotherapy-induced nausea and vomiting (CINV): results of a phase 3 study of NEPA (fixed-dose combination of netupitant and palonosetron)
    Jahn, P.
    Jordan, K.
    Rizzi, G.
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2014, 18 : S20 - S21
  • [28] Palonosetron (PALO), administered orally or intravenously (IV), plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting (CINV)
    Boccia, R. V.
    Gonzalez, E. F.
    Pluzanska, A. G.
    Clerici, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] NEPA <sc>(</sc>Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial
    Navari, Rudolph M.
    Bonizzoni, Erminio
    CANCER MEDICINE, 2025, 14 (07):
  • [30] Palonosetron (PALO) is effective in preventing chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 94 - 95
12345